Taking melatonin for a year could increase a person's risk of developing heart failure by 90%. While more research is still needed to confirm these findings, the data suggest patients should think twice about relying on melatonin to sleep.
Novo Nordisk and Eli Lilly have agreed to sell their popular Wegovy and Zepbound injectables through TrumpRx.gov for a discounted rate, as the White House promises that Medicaid and Medicare plans will begin covering the costs.
Authorities said in a court filing that they received a complaint about Northeast Ohio Neighborhood Health Services’ business practices. The health system owes more than $12 million to creditors, and investigators are asking to see its financial records.
The company will analyze claims data from over 2 million people enrolled in Medi-Cal. The data will be used for compliance reporting and to improve patient care coordination.
SIR contends that payments toward transarterial radioembolization (TARE)/selective internal radiation therapy (SIRT) should extend beyond the current coverage limitations in patients with liver cancer and metastases.
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
Bleeding events remain a serious complication after TAVR. By identifying high-risk patients early and planning ahead, however, care teams can keep them to a minimum.
Clinicians who come to rely on AI for decision support risk the dulling of their skills.The concern is not new. But now comes a pointed call to researchers: Inquire about the particulars of the peril.
Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.
Taking melatonin for a year could increase a person's risk of developing heart failure by 90%. While more research is still needed to confirm these findings, the data suggest patients should think twice about relying on melatonin to sleep.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
